Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre ,[1] which is an institute of the Russian Academy of Sciences.[2] It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[1] It obtained a permission for phase III clinical trial on 2 June 2021.[3]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search